Inventiva is a biopharmaceutical company developing oral small molecule therapies targeting non-alcoholic steatohepatitis (NASH) and mucopolysaccharidoses (MPS), utilizing a proprietary library of compounds and expertise in nuclear receptor modulation. Their lead candidates, lanifibranor and odiparcil, aim to address significant unmet medical needs by improving liver health and modifying glycosaminoglycan synthesis in affected patients.
Funding
$126M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BVFounders
Product
Problem
Non-alcoholic steatohepatitis (NASH) and mucopolysaccharidoses (MPS) are diseases with significant unmet medical needs. NASH requires treatments addressing steatosis, hepatitis, ballooning, and fibrosis to prevent cirrhosis. MPS disorders, characterized by glycosaminoglycan accumulation, lack therapies that effectively modify GAG synthesis and distribution.
Solution
Inventiva is a biopharmaceutical company focused on developing oral small molecule therapies for NASH and MPS. Their lead drug candidate, lanifibranor, targets NASH by inducing anti-fibrotic, anti-inflammatory, and beneficial metabolic changes through PPAR activation. Another clinical-stage asset, odiparcil, is designed to treat MPS by modifying GAG synthesis, facilitating the production of soluble GAGs for excretion. Inventiva leverages a library of proprietary molecules and expertise in nuclear receptor modulation to advance clinical candidates and a preclinical pipeline in fibrosis and oncology.
Target Audience
The primary target audience includes patients suffering from NASH and MPS, as well as healthcare providers specializing in the treatment of these conditions.
Features
- Lanifibranor: Orally-available small molecule that activates all three peroxisome proliferator-activated receptor (PPAR) isoforms to treat NASH
- Odiparcil: Orally-available small molecule that modifies glycosaminoglycan (GAG) synthesis to treat MPS
- Extensive library of proprietary molecules for drug discovery
- Wholly-owned research and development facility
- Focus on oral small molecule therapies for fibrosis, lysosomal storage disorders, and oncology
- Clinical programs: NATiV3 (Phase III trial in NASH), iMProveS (Phase IIa study in MPS VI)
- Pre-clinical pipeline in oncology and fibrosis